Key Highlights
- CalciMedica reported a net loss of $7.7 million and cash of $18.6 million as of June 30, 2026, aided by a roughly $49 million private Placement completed in late June.
- On July 29, 2026, the company reached alignment with the FDA on a Phase 2b trial design for Auxora in acute pancreatitis.
- Its KOURAGE trial in acute kidney injury with respiratory failure was paused in January 2026 over a mortality imbalance, and the company does not plan to restart it.
- CALC shares plunged, a sharp move for a stock that had otherwise traded quietly while awaiting regulatory and funding milestones.
CalciMedica, Inc. (NASDAQ:CALC), a clinical-stage biotechnology company developing therapies that target calcium-release-activated calcium (CRAC) channels, saw its shares plunge sharply even as it works to recalibrate its pipeline and line up the financing to advance its lead asset. The scale of the drop underscores how quickly sentiment can turn in a small biotech name once questions about funding and trial risk come into focus.
CalciMedica's lead candidate, Auxora, is an intravenous CRAC-channel inhibitor aimed at serious inflammatory conditions. Its most advanced opportunity is in acute pancreatitis, a disease with no approved targeted therapies, where the company has been working to define a registrational path, a potentially valuable niche if the science and trial design hold up.
Latest developments
In its second-quarter 2026 update, CalciMedica reported a net loss of $7.7 million ($0.45 per share) and cash of $18.6 million as of June 30, 2026, which it expects to fund operations into the second half of 2027, aided by a roughly $49 million private placement completed in late June. On July 29, 2026, the company said it reached alignment with the FDA on a Phase 2b trial design for Auxora in acute pancreatitis, with a primary endpoint focused on reducing new-onset severe respiratory failure.
It also disclosed that its KOURAGE trial in acute kidney injury with respiratory failure was paused in January 2026 over a mortality imbalance, with no drug-related toxicity identified, and that it does not plan to restart that study.
Financial and Business position
The recent financing and extended runway give CalciMedica the flexibility to pursue its priorities, though management noted that initiating the acute-pancreatitis Phase 2b remains subject to additional funding. The paused KOURAGE study is a reminder that CRAC-channel modulation in critically ill patients carries real clinical risk.
Stock-market context
CALC shares plunged sharply, a significant move for a stock that carries a favorable analyst rating in the underlying data. The drop is consistent with a market weighing the real financing gap between current cash and the funding needed to launch the Phase 2b study, on top of lingering caution from the paused KOURAGE trial; the risk is that a small biotech dependent on additional financing can see its shares fall further if Capital is raised dilutively or timelines slip.
What investors should watch
Key milestones include confirmation of financing to initiate the acute-pancreatitis Phase 2b, the trial's start and design details, the mid-2027 pulmonary-hypertension Phase 1b readout, and the planned oral CRAC inhibitor IND.
A Steep Drop Tied to a Real Funding Gap
CalciMedica's approach targets an underappreciated biological pathway, and securing FDA alignment on a Phase 2b design is a genuinely valuable de-risking step in a disease where the regulatory path has historically been murky. That said, the paused KOURAGE trial and the funding still required to start the next study help explain why the stock's sharp decline reflects real, unresolved questions rather than a simple overreaction.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...